Chimerix to Participate in Upcoming Investor Conferences
September 10 2020 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that management will participate
in the following investor conferences in September:
- H.C. Wainwright 22nd Annual Global Investment
Conference: Chimerix will present a corporate overview on
Monday, September 14 at 1:00 p.m. ET and participate in investor
meetings.
- Cantor Fitzgerald Virtual Healthcare
Conference: Management will participate in investor
meetings on Wednesday, September 16.
A live audio webcast of the H.C. Wainwright conference
presentation will be available on the Investor Relations section of
Chimerix's website at ir.chimerix.com, where it will be archived
for approximately 90 days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Its two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
DSTAT is a potential first-in-class glycosaminoglycan compound
derived from porcine heparin that, compared to commercially
available forms of heparin, may be dosed at higher levels without
associated bleeding-related complications. DSTAT is being
studied in a Phase 2/3 trial to assess safety and efficacy in
adults with acute lung injury with underlying COVID-19. A
Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has
been agreed to with the US Food and Drug Administration (FDA) and
site activation is expected in early 2021. BCV is an
antiviral drug candidate in development as a medical countermeasure
for smallpox. For further information, please visit the Chimerix
website, www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Factors and
risks that could cause actual results to differ materially from
those indicated in the forward-looking statements are set forth in
the Company's filings with the Securities and Exchange
Commission. These forward-looking statements represent the
Company's judgment as of the date of this release. The Company
disclaims, however, any intent or obligation to update these
forward-looking statements.
CONTACT:Investor
Relations:
Michelle LaSpaluto 919 972-7115 ir@chimerix.com Will O’Connor Stern
Investor Relations212-362-1200 will@sternir.com
Media:David SchullRusso
Partners858-717-2310David.Schull@russopartnersllc.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024